Evaluation of eltrombopag in thrombocytopenia post Hematopoietic cell transplantation

Thrombocytopenia remains a life-threatening late complication of HCT with an incidence of 5–20%. Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT and platelet transfusion is the maintain stay of treatment. Eltrombopag is approved for the treatment of thrombocytopenia associated with different diseases, however; data on eltrombopag treatment post HSCT are limited.